Good Distribution Practices Under Canada GMP: What Pharmaceutical Distributors Need to Know

Somewhere between the pallet wrapper and the pharmacy cold room, product integrity can silently fail. A single temperature excursion during transit — three hours at 32°C in a summer delivery van — can degrade a biologic below its minimum potency threshold before anyone opens the box. The drug looks fine. The label says “Store at 2°C–8°C.” The patient takes it. And no one knows.

This is exactly the kind of failure that Health Canada’s Good Distribution Practices (GDP) framework is designed to prevent. And for Canadian pharmaceutical manufacturers, importers, and distributors, understanding where your obligations begin and end under Canada GMP isn’t optional — it’s written directly into the Food and Drug Regulations.

What surprises many companies entering the Canadian market is just how far GMP obligations extend into distribution activities. It’s not a separate, lighter regime. Health Canada treats distribution as a downstream extension of manufacturing quality, and inspection findings in distribution operations are scored and tracked the same way as manufacturing deficiencies.

What Health Canada’s GDP Framework Actually Covers

Canada doesn’t have a standalone GDP Act. Instead, Good Distribution Practices sit within the broader GMP framework established in Part C, Division 2 of the Food and Drug Regulations. Health Canada’s primary guidance document — GUI-0001, the Good Manufacturing Practices Guide for Drug Products — addresses distribution activities directly, covering storage conditions, handling requirements, and the responsibilities of importers and distributors operating under Canadian licences.

Since Canada joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2013, its GMP expectations have aligned closely with PIC/S standards, including the PIC/S Guide to Good Distribution Practice for Medicinal Products (PI 041-1). That alignment matters practically: Health Canada inspectors evaluate distribution sites using the same framework as EMA-aligned regulators in Europe, which means the bar is high and consistent.

Practically speaking, GDP compliance obligations under Canada GMP apply to any organization that:

• Imports drugs into Canada under an Establishment Licence (EL)
• Distributes or wholesales licensed drug products domestically
• Provides third-party warehousing or logistics services for pharmaceutical products
• Manages a cold chain for temperature-sensitive biologics, vaccines, or sterile preparations

The Establishment Licence requirement is often where companies first encounter Canada GMP in a distribution context. Under the Food and Drug Regulations, any person who distributes, imports, or sells a drug in Canada — including foreign manufacturers shipping product to a Canadian importer — is subject to EL requirements and must demonstrate GMP compliance as part of the licensing process. That compliance demonstration isn’t self-certified; Health Canada can and does inspect sites before and after licence issuance.

The Core Requirements: Canada GMP Applied to Distribution Operations

The specific GDP obligations under Canada GMP group into five operational areas. Each is an active inspection target.

Qualified personnel and organizational accountability. Health Canada expects a designated Quality Assurance function with documented authority over distribution operations. That means authority to quarantine product, approve or reject deviations, and initiate recalls — independent of commercial pressure. In practice, your QA designate can’t be the same person whose performance targets depend on clearing shipments by month-end. The organizational separation needs to be demonstrable, not just stated in an org chart.

Premises and storage conditions. Controlled Room Temperature (CRT) under Canadian and ICH standards means 15°C to 30°C, with brief excursions permitted up to 40°C — but “brief” must be defined and qualified through your stability program, not interpreted informally. Refrigerated products must maintain 2°C to 8°C throughout storage, and frozen products are typically held at -20°C or below. Segregation of quarantined, rejected, recalled, and released product is mandatory, and it must be physically demonstrable to an inspector doing a floor walk. A locked cage with a “Quarantine” label is a start; an unlocked shelf with a paper sign is a deficiency.

Warehouse temperature monitoring and qualification. Mapping your storage areas is not merely best practice under Canada GMP — it’s expected. Health Canada inspectors will ask to see your temperature mapping study, including the number and placement of monitoring points, the duration of the study (typically a minimum of several days under loaded conditions), and how the mapping accounts for seasonal variation. Both summer and winter profiles should be on file. A single thermostat mounted near the door doesn’t qualify.

Transportation controls. This is where many Canadian distributors have unaddressed gaps. Canada GMP extends GMP accountability to contracted carriers and logistics providers. Your GDP program must include a formal process for qualifying transportation vendors, monitoring temperature during transit — whether through data loggers, validated insulated shipper studies, or real-time IoT monitoring — and maintaining that qualification documentation. If a third-party carrier is transporting your product across three provinces in July, your EL holder is still accountable for what happens in that trailer. “We used a reputable courier” is not a qualification.

Documentation and batch traceability. Distribution records must support complete forward and reverse traceability: from the manufacturer’s batch number, through every intermediate handler, to the point of final delivery. Health Canada inspectors have traced individual pallets through distribution chains during inspections. If you can’t reconstruct a batch’s movement within 30 minutes using your records system, your documentation doesn’t meet the standard.

Temperature Excursions: The Gap That Generates the Most Inspection Findings

Temperature excursion management is consistently one of the most cited deficiency areas in distribution inspections — not because companies don’t know excursions happen, but because their deviation and investigation processes aren’t scientifically robust enough to satisfy a regulatory reviewer.

The WHO estimates that approximately 20% of temperature-sensitive pharmaceuticals experience at least one excursion during global distribution. In the Canadian regulatory context, a documented excursion requires a formal investigation and documented disposition decision. Product involved in an uninvestigated excursion must be quarantined until that disposition is made. “It probably stayed cold enough” is not a conclusion Health Canada will accept in a deviation record.

What a defensible excursion investigation looks like in practice:

1. A written deviation report with a timestamp tied to the temperature monitoring data — not a retroactive summary written a week later
2. A product impact assessment based on the stability profile of the specific product, conducted for the actual excursion duration and temperature range
3. A documented disposition decision (release, reject, or additional stability testing) made by an authorized QA person
4. A corrective and preventive action (CAPA) if the excursion reflects a systemic pattern — a carrier consistently delivering outside the transit window, a loading dock with no temperature control during summer months

Companies that handle excursions this way — with contemporaneous records and scientific rationale — rarely face Critical findings in this area. Companies that rely on informal email chains and verbal sign-offs routinely collect Major deficiencies.

Getting Ready for a Health Canada Distribution Site Inspection

Health Canada conducts risk-based inspections of licensed distribution sites, with frequency tied to the licence activity level and the site’s prior inspection history. For a facility with a clean record, inspection intervals can range from three to five years. Sites with open CAPAs, prior Critical deficiencies, or significant changes to operations can expect more frequent contact.

The inspection typically covers four areas: QMS documentation review (SOPs, master document list, training records for relevant personnel), a physical walk-through of storage areas with particular attention to segregation and monitoring equipment, records review (recent deviations, complaints, temperature logs, and recall-related documentation), and personnel interviews. Your QA designate should be able to speak to your GDP procedures without needing to consult the binder.

One thing that regularly catches distributors off guard: Health Canada inspectors may request evidence of a recent mock recall exercise. The expectation is that you can demonstrate 100% forward traceability of a selected batch within a defined timeframe — typically 4 hours for a Class I recall scenario. If you haven’t conducted a mock recall in the past 12 months, that’s a gap worth addressing before the inspector arrives. Run one, document the results, and follow up on any traceability failures with corrective action.

Three Things to Fix Before Your Next Inspection

Canada GMP for distribution isn’t a lighter version of manufacturing GMP — it’s the same framework applied to a different operational context. The documentation expectations, qualification requirements, and inspection scrutiny are equivalent.

If you’re building or auditing a Canadian GDP program right now, three areas deserve priority attention. First: warehouse temperature mapping with both summer and winter qualification data. Second: a formal, documented transportation vendor qualification process that includes monitoring data from actual shipments — not just carrier certifications on file. Third: a deviation management workflow that produces timely, scientifically defensible excursion investigations, not informal email records.

Get those three right and you’ll be ahead of the majority of distribution sites that collect GDP-related findings in Canada. And if you’re in the early stages of securing an Establishment Licence, bring a complete, implemented quality system to the pre-licence review. Companies that do this consistently move through licensing faster than those that treat it as a documentation exercise they’ll finish after the licence arrives.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• ISO 17025-Accredited Lab Testing for US Pharmaceutical Manufacturers — Qalitex Laboratories provides FDA-aligned cGMP and ISO 17025 testing services for supplement and pharmaceutical manufacturers in the United States.
• EU Good Distribution Practice and Regulatory Compliance for Consumer Health Products — Care Europe covers EU regulatory requirements, including REACH and EU 1223/2009, for companies entering or operating in the European market.